drugset / Trial / NCT00345163

A Study to Evaluate Bevacizumab Alone or in Combination With Irinotecan for Treatment of Glioblastoma Multiforme (BRAIN)

NCT00345163 ↗

Phase 2 Completed 167 enrolled Genentech, Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a Phase II, open-label, multicenter, randomized, non comparative study consisting of two concurrent single-arms. Approximately 160 subjects will be randomized in a 1:1 ratio to Arm 1 (bevacizumab alone) or Arm 2 (bevacizumab + irinotecan).

Timeline

Start
2006-07
Primary completion
2007-09
Completion
2007-09

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Bevacizumab Monoclonal antibody 10 mg/kg Intravenous
Subject Irinotecan Small molecule 125 mg/m2 Intravenous
Subject Irinotecan Small molecule 340 mg/m2 Intravenous

Indications